Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45

Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $47 to $45.